Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients

Ähnliche Einträge

• Reply to: Comment on: Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients
  von: Anne Spence, et al.
  Veröffentlicht: (2025)
• Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors
  von: Maria Frost, et al.
  Veröffentlicht: (2026)
• Increasing Access to Pediatric Allogeneic Hematopoietic Stem Cell Transplantation in South Africa
  von: Candice Laverne Hendricks, et al.
  Veröffentlicht: (2026)
• Procedural Sedation outside the Operating Room in Pediatric Hematopoietic Stem Cell Transplant Patients
  von: Heather Xiao, et al.
  Veröffentlicht: (2026)
• Soluble Thrombomodulin Is Associated With Endothelial Dysfunction Syndromes After Pediatric Hematopoietic Stem Cell Transplantation
  von: Denise Elbæk Horan, et al.
  Veröffentlicht: (2025)